Compare Royal Bank of Canada (RY) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Royal Bank of Canada vs TG Therapeutics Inc — how do they compare? Royal Bank of Canada trades at $206.91 (market cap $286.95B), while TG Therapeutics Inc trades at $54.77 (market cap $8.36B). The key difference: Royal Bank of Canada is far larger — about 34.3× TG Therapeutics Inc's market cap, and Royal Bank of Canada pays a 2.45% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals.
| RY | TGTX | |
|---|---|---|
Market Cap | $286.95B | $8.36B |
Sector | Financials | Health |
52-Week High | $217.87 | $59.06 |
52-Week Low | $143.64 | $26.94 |
Dividend Yield | 2.45% | — |
Enterprise Value | — | $8.57B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Royal Bank of Canada (RY) trades at $209.00, down 0.76% on the day, with strong technical momentum showing bullish moving averages and support at $208. The company delivered three consecutive earnings beats, with Q2 2026 EPS of $3.07 exceeding expectations, while revenue grew to $66.53 billion in 2025 with a robust 32.01% net income margin. Recent news highlights record quarterly earnings and dividend declarations.
RY presents a compelling investment case with consistent earnings outperformance and strong profitability metrics, though stretched valuations and mixed analyst sentiment warrant caution. The stock's technical strength and fundamental growth support upside potential, but investors should monitor debt levels and competitive pressures in the banking sector.
TG Therapeutics (TGTX) trades at $55.74, down 0.44% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $64.00. The company reported strong revenue growth, with Q2 2026 revenue reaching $240 million and full-year 2026 guidance raised to approximately $950 million, though recent quarterly EPS results have missed expectations. News highlights include conference participation and institutional buying interest, supporting positive sentiment.
The outlook remains optimistic driven by Briumvi's commercial growth and pipeline catalysts, but risks include earnings volatility, competitive pressures, and reliance on a key product. Upside potential exists if execution meets raised guidance, making it a focus for growth-oriented investors despite near-term profit misses.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Royal Bank of Canada
Royal Bank of Canada is one of the two largest banks in Canada. It is a diversified financial services company, offering personal and commercial banking, wealth-management services, insurance, corporate banking, and capital markets services. The bank is concentrated in Canada, with additional operations in the U.S. and other countries.
Read more on RY →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
